An interventional study of Standardized Carpal Tunnel Syndrome Rehabilitation and Psychologically Informed Pain-Management Program in Carpal Tunnel Syndrome and Pain, Chronic, sponsored by Ahram Canadian University. Completed at 1 site in Egypt. Open to participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Ahram Canadian University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Carpal Tunnel Syndrome by Ahram Canadian University — 5 open to participants now, 5 under way, none of them phase 3. Carpal Tunnel Syndrome · Ahram Canadian University.
Among the 10 studies in Carpal Tunnel Syndrome by Ahram Canadian University, this one is one of 10 that started in 2023, is one of 3 with no phase, and was the 7th registered.
591 studies on the registry are indexed under Carpal Tunnel Syndrome; 133 are open to participants now.
Browse Carpal Tunnel Syndrome studies →5 of the 10 studies in Carpal Tunnel Syndrome by Ahram Canadian University are open now, in 1 country. Recruiting first, the newest first:
Ahram Canadian University · Sites in Egypt
Ages 18–60 · Healthy volunteers
Ahram Canadian University · Sites in Egypt
Ages 18–45 · Healthy volunteers
Ahram Canadian University · Sites in Egypt
Ages 18–60
Ahram Canadian University · Sites in Egypt
Ages 18–60
Ahram Canadian University · Sites in Egypt
Ages 18–60
By country, each count listing its studies:
Of the 72 Carpal Tunnel Syndrome studies recruiting now, 27 (38%) set no upper age limit and 36 (50%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.
This study: 25 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2023; this study’s year is marked. 10 started in 2023.
This study's enrollment of 178 is above the median of 60 across 446 interventional studies indexed under Carpal Tunnel Syndrome.
Median enrollment 92 across the 3 interventional studies, 50 across the 7 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ahram Canadian University is the lead sponsor of 71 studies on the registry; 41 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Carpal Tunnel Syndrome by Ahram Canadian University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized, assessor-blinded, parallel-group trial evaluated the effectiveness of adding a psychologically informed pain-management intervention to standardized physical rehabilitation in adults with electrodiagnostically confirmed carpal tunnel syndrome and coexisting mixed neuropathic-nociplastic pain features. A total of 178 participants were randomized in a 1:1 ratio. The active treatment period lasted 6 weeks, with follow-up through 12 weeks after randomization. The primary outcome was the Boston Carpal Tunnel Questionnaire-Symptom Severity Scale at 6 weeks.
This randomized, assessor-blinded, parallel-group trial evaluate whether adding a psychologically informed pain-management intervention to standardized physical rehabilitation improves carpal tunnel syndrome symptoms in adults with electrodiagnostically confirmed carpal tunnel syndrome and coexisting nociplastic pain features. A total of 178 participants will be randomized in a 1:1 ratio to receive either standardized physical rehabilitation plus a psychologically informed pain-management program or the same standardized physical rehabilitation plus attention-matched health education. The active treatment period will last 6 weeks, with follow-up at 12 weeks after randomization. The primary outcome will be the Boston Carpal Tunnel Questionnaire-Symptom Severity Scale at 6 weeks. Secondary outcomes will assess pain intensity, hand function, pain catastrophizing, kinesiophobia, upper-extremity disability, patient-perceived improvement, pain-processing characteristics, grip strength, and median-nerve electrophysiological measures.
The criteria were revised on the registry on Oct 9, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive standardized physical rehabilitation for carpal tunnel syndrome together with a structured psychologically informed pain-management program for 6 weeks. Standardized rehabilitation will include night-time neutral-position wrist splinting, supervised flexor-tendon gliding and median-nerve neurodynamic exercises, education regarding symptom-provoking activities, and a standardized home-exercise program. Participants will additionally receive six individual psychologically informed pain-management sessions, approximately 40-45 minutes each, delivered once weekly.
Other: Standardized Carpal Tunnel Syndrome Rehabilitation · Behavioral: Psychologically Informed Pain-Management Program
Participants will receive the same standardized physical rehabilitation and home-exercise program as the experimental group for 6 weeks. In addition, participants will receive six individual attention-matched health-education sessions, approximately 40-45 minutes each, delivered once weekly. The health-education sessions will address general healthy lifestyle, sleep hygiene, physical activity, and hand health without including the specific psychologically informed pain-management components provided to the experimental group.
Other: Standardized Carpal Tunnel Syndrome Rehabilitation · Behavioral: Attention-Matched Health Education
Participants will receive a standardized 6-week physical rehabilitation program for carpal tunnel syndrome. Treatment will include night-time neutral-position wrist splinting, flexor-tendon gliding exercises, median-nerve neurodynamic exercises, education regarding activities that provoke symptoms, and a standardized home-exercise program. Supervised physical therapy will be provided twice weekly for 6 weeks, for a total of 12 supervised sessions. Participants will be instructed to perform the prescribed home exercises between supervised sessions.
Participants will receive six individual psychologically informed pain-management sessions, approximately 40-45 minutes each, delivered once weekly over 6 weeks. The program will include pain neuroscience education, identification and modification of maladaptive pain beliefs, cognitive restructuring, strategies to reduce pain catastrophizing and fear of movement, graded exposure to feared upper-extremity activities, activity pacing, coping and self-management strategies, and relapse-prevention planning. The intervention will be delivered in addition to standardized CTS rehabilitation.
Participants will receive six individual health-education sessions, approximately 40-45 minutes each, delivered once weekly over 6 weeks. Sessions will be matched approximately to the experimental psychological intervention for therapist contact, frequency, and duration. Content will include general information regarding healthy lifestyle, sleep hygiene, physical activity, and general hand health. The sessions will not include pain neuroscience education, cognitive restructuring, pain-catastrophizing management, graded exposure, or other specific psychologically informed pain-management strategies.
Boston Carpal Tunnel Questionnaire - Symptom Severity Scale (BCTQ-SSS)
Carpal tunnel syndrome symptom severity will be assessed using the 11-item Symptom Severity Scale of the Boston Carpal Tunnel Questionnaire. Each item is scored from 1 to 5, and the total scale score is calculated as the mean of the completed items, with higher scores indicating greater symptom severity. The primary endpoint is the BCTQ-SSS score at 6 weeks after randomization.
Time frame: Baseline and 6 weeks after randomization.
Boston Carpal Tunnel Questionnaire - Symptom Severity Scale (BCTQ-SSS) Score at 12 Weeks
Carpal tunnel syndrome symptom severity will be assessed using the 11-item Symptom Severity Scale of the Boston Carpal Tunnel Questionnaire (BCTQ-SSS). Each item is scored from 1 to 5. The scale score is calculated as the mean of the completed items and ranges from 1 to 5, with higher scores indicating greater symptom severity. The 12-week assessment will evaluate maintenance of the treatment effect after completion of the 6-week intervention period.
Time frame: Baseline and 12 weeks after randomization.
Pain catastrophizing using the Pain Catastrophizing Scale (PCS)
Pain-related catastrophic thinking will be assessed using the 13-item Pain Catastrophizing Scale (PCS), which evaluates rumination, magnification, and helplessness related to pain. Each item is scored from 0 to 4, producing a total score ranging from 0 to 52. Higher scores indicate greater pain catastrophizing.
Time frame: Baseline, 3 weeks, 6 weeks, and 12 weeks after randomization.
Fear of movement using the Tampa Scale for Kinesiophobia (TSK)
Fear of movement and pain-related movement avoidance will be assessed using the 11-item Tampa Scale for Kinesiophobia (TSK-11). Each item is scored on a 4-point scale, producing a total score ranging from 11 to 44. Higher scores indicate greater kinesiophobia.
Time frame: Baseline, 3 weeks, 6 weeks, and 12 weeks after randomization.
Grip strength measured using a hand dynamometer
Maximum voluntary grip strength of the study hand will be measured using a calibrated hand dynamometer in a standardized seated position. Three trials will be performed with a prespecified rest interval between trials. The mean of the three trials, expressed in kilograms, will be used for analysis. Higher values indicate greater grip strength.
Time frame: Baseline, 6 weeks, and 12 weeks after randomization.
Numeric Pain Rating Scale for CTS-Related Hand and Wrist Pain
Description: Average carpal tunnel syndrome-related hand and wrist pain during usual activities over the previous 7 days will be assessed using an 11-point Numeric Pain Rating Scale (NPRS), ranging from 0 to 10, where 0 represents no pain and 10 represents the worst imaginable pain. Higher scores indicate greater pain intensity.
Time frame: Baseline, 6 weeks, and 12 weeks after randomization.
Boston Carpal Tunnel Questionnaire - Functional Status Scale (BCTQ-FSS)
Carpal tunnel syndrome-related functional limitation will be assessed using the 8-item Functional Status Scale of the Boston Carpal Tunnel Questionnaire (BCTQ-FSS). Each item is scored from 1 to 5. The scale score is calculated as the mean of the completed items and ranges from 1 to 5, with higher scores indicating greater difficulty performing activities commonly affected by carpal tunnel syndrome.
Time frame: Baseline, 6 weeks, and 12 weeks after randomization.
Disabilities of the Arm, Shoulder and Hand (DASH) Score
Upper-extremity symptoms and disability will be assessed using the 30-item Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire. The DASH score ranges from 0 to 100, with higher scores indicating greater upper-extremity disability and symptom severity.
Time frame: Baseline, 6 weeks, and 12 weeks after randomization.
Central Sensitization Inventory (CSI)
Symptoms associated with central sensitization-related presentations will be assessed using Part A of the Central Sensitization Inventory (CSI). The 25 items are scored from 0 to 4 and summed to produce a total score ranging from 0 to 100. Higher scores indicate greater self-reported symptom burden associated with central sensitization-related presentations. The CSI will be used as a symptom-burden and phenotyping measure and not as a stand-alone diagnostic test for nociplastic pain.
Time frame: Baseline, 6 weeks, and 12 weeks after randomization.
Patient Global Impression of Change (PGIC)
Participant-perceived overall change in carpal tunnel syndrome symptoms and functional status since the beginning of treatment will be assessed using the Patient Global Impression of Change (PGIC). Participants will rate their overall change using a 7-category scale ranging from "very much improved" to "very much worse." Responses will be analyzed as an ordinal measure of patient-perceived improvement or deterioration.
Time frame: 6 weeks and 12 weeks after randomization.
Median Nerve Motor Distal Latency
Median nerve motor distal latency will be measured using standardized nerve conduction testing, with stimulation of the median nerve and recording from the abductor pollicis brevis muscle. Distal motor latency will be recorded in milliseconds. Longer latency indicates greater slowing of median nerve motor conduction across the wrist.
Time frame: Baseline and 12 weeks after randomization.
Median Nerve Sensory Distal Latency
Median nerve sensory distal latency will be measured using standardized sensory nerve conduction testing. Distal sensory latency will be recorded in milliseconds. Longer latency indicates greater slowing of median nerve sensory conduction across the wrist.
Time frame: Baseline and 12 weeks after randomization.
Median Nerve Compound Muscle Action Potential (CMAP) Amplitude
Median nerve compound muscle action potential (CMAP) amplitude will be obtained during standardized motor nerve conduction testing and recorded in millivolts. CMAP amplitude provides an electrophysiological measure of motor axonal response.
Time frame: Baseline and 12 weeks after randomization.
median Nerve Sensory Nerve Action Potential (SNAP) Amplitude
Median nerve sensory nerve action potential (SNAP) amplitude will be obtained during standardized sensory nerve conduction testing and recorded in microvolts. SNAP amplitude provides an electrophysiological measure of sensory axonal response.
Time frame: Baseline and 12 weeks after randomization.
Median Nerve Sensory Conduction Velocity
Median nerve sensory conduction velocity will be calculated from standardized sensory nerve conduction testing and expressed in meters per second. Lower conduction velocity indicates greater slowing of median nerve sensory conduction.
Time frame: Baseline and 12 weeks after randomization.
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2023 to primary completion in May 2026, 34 months.
Of 252 non-industry interventional studies with no phase under Carpal Tunnel Syndrome, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 27. This study's 34 months is above that.
Counting every sponsor, half of 262 studies reached it within 12 months; a quarter within 7 and three quarters within 26.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: start Jun 2023 → Jul 2023, primary completion Sep 2024 → May 2026 and completion Sep 2024 → Jun 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ahram Canadian University